Jaguar Health Highlights Promising Study Results for Crofelemer in Pediatric Intestinal Failure

Jaguar Health, Inc. has summarized findings from a recent trial presented at the 2025 NASPGHAN Annual Meeting. The study evaluated crofelemer for pediatric intestinal failure, focusing on patients with microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF). Notably, crofelemer showed potential in significantly reducing parenteral support (PS) needs, with results indicating a reduction of up to 37% in PS requirements for MVID patients.

Lisa Conte, CEO of Jaguar Health, explained that patients with these conditions lack adequate intestinal function, necessitating life-sustaining PS. Crofelemer's ability to minimize this need addresses a critical treatment gap, given the absence of approved MVID therapies.

This independent trial, led by Dr. Mohamad Miqdady, marks a significant step forward, suggesting crofelemer could alter the disease progression by decreasing PS needs and improving patient quality of life.